特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
938725

白血病治療の世界市場:2025年までの予測と市場機会

Global Leukemia Therapeutics Market By Factor, By Severity, By Blood Cell, By Age Groups, By Sex, By Treatment, By Diagnosis, By Route of Administration, By Drugs, By Region, Forecast & Opportunities, 2025

出版日: | 発行: TechSci Research | ページ情報: 英文 110 Pages | 納期: お問合せ

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

白血病治療の世界市場:2025年までの予測と市場機会
出版日: 2020年05月01日
発行: TechSci Research
ページ情報: 英文 110 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 目次
概要

世界の白血病治療市場は、予測期間中に堅調な速度で成長すると予想されます。 市場は、白血病に苦しむ患者の増加に伴う血液癌検査の分野における技術の進歩と革新によって推進されています。さらに、予防医療の採用に関する意識の高まりや、がんへの認識を促進するための支援的な政府の取り組みと政策は、2025年まで市場の成長を後押しすると予想されます。

当レポートは、世界の白血病治療市場をセグメント別や地域別で調査したもので、市場規模および市場シェアの予測、促進要因と課題、市場動向、競合情勢、企業プロファイルなどの情報を提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の白血病治療市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 要因別(人工電離放射線、ウイルス、化学療法、遺伝学、免疫抑制、その他)
    • 重症度別(急性、慢性)
    • 血液細胞別(リンパ球性、骨髄性)
    • 年齢層別(0-15、15-30、30-50、50 +)
    • 性別(男性、女性)
    • 治療別(標的療法、インターフェロン療法、放射線療法、手術、幹細胞移植、薬物、遺伝子治療、免疫療法、ワクチン療法、化学療法、輸血)
    • 診断別(血液検査、生検、身体検査、画像検査(CT-SCAN、X-RAY、MRI))
    • 投与経路別(経口、静脈内、皮下、筋肉内、髄腔内)
    • 薬物別(抗タイムボライト、バイオシミラー、アスパラギン特異的酵素、ホルモン(コルチコステロイド)、低メチル化(脱メチル化)剤、チロシンキナーゼ阻害剤、その他)
    • 会社別
    • 地域別
  • 市場魅力指数

第6章 アジア太平洋の白血病治療市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 要因別
    • 重症度別
    • 血液細胞別
    • 年齢別
    • 性別
    • 治療別
    • 診断別
    • 投与経路別
    • 薬物別
    • 国別
  • 市場魅力指数
  • アジア太平洋:国分析
    • 中国
    • インド
    • 日本
    • 韓国
    • シンガポール
    • オーストラリア

第7章 欧州の白血病治療市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 要因別
    • 重症度別
    • 血液細胞別
    • 年齢別
    • 性別
    • 治療別
    • 診断別
    • 投与経路別
    • 薬物別
    • 国別
  • 市場魅力指数
  • 欧州:国分析
    • フランス
    • ドイツ
    • 英国
    • イタリア

第8章 北米の白血病治療市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 要因別
    • 重症度別
    • 血液細胞別
    • 年齢別
    • 性別
    • 治療別
    • 診断別
    • 投与経路別
    • 薬物別
    • 国別
  • 市場魅力指数
  • 北米:国分析
    • 米国
    • メキシコ
    • カナダ

第9章 南米の白血病治療市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 要因別
    • 重症度別
    • 血液細胞別
    • 年齢別
    • 性別
    • 治療別
    • 診断別
    • 投与経路別
    • 薬物別
    • 国別
  • 市場魅力指数
  • 南米:国分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの白血病治療市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 要因別
    • 重症度別
    • 血液細胞別
    • 年齢別
    • 性別
    • 治療別
    • 診断別
    • 投与経路別
    • 薬物別
    • 国別
  • 市場魅力指数
  • 中東・アフリカ:国分析
    • 南アフリカ
    • サウジアラビア
    • UAE

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

第13章 競合情勢

  • 競合の展望
  • 主要企業プロファイル
    • Novartis
    • AbbVie
    • Bristol-Myers Squibb
    • Roche
    • Amgen
    • Gilead sciences
    • Celgene
    • Eisai
    • AstraZeneca
    • Incyte Corporation
    • Johnson & Johnson
    • Biogen
    • Merck
    • PerkinElmer
    • Eli Lilly
    • Abbott
    • Sumitomo Dainippon Pharma
    • Thermo Fisher Scientific
    • Otsuka Holdings
    • Astellas Pharma

第14章 戦略的推奨事項

第15章 免責事項

目次
Product Code: 4534

Leukemia or blood cancer is the cancer of blood forming tissues: bone marrow and lymphatic system. As the name suggests, it affects the leucocytes or white blood cells. In this type of cancer, the DNA of leucocytes gets damaged as a result of which they grow and divide uncontrollably. These cells keep on growing and start accumulating, thereby preventing the healthy white blood cells from growing and functioning.

Global leukemia therapeutics market is expected to grow at a formidable rate during the forecast period. The global leukemia therapeutics market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Furthermore, supportive government initiatives & policies for promoting cancer awareness is anticipated to fuel the market growth until 2025.

The global leukemia therapeutics market can be segmented based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and region. Based on severity, the market can be bifurcated into acute and chronic. The chronic leukemia segment is expected to dominate the market during forecast period. This can be accredited to the rising geriatric population and increasing funding for cancer research and the development of new therapies.

Regionally, the leukemia therapeutics market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market during forecast period. This can be attributed to the presence of a large geriatric population base in the country. Additionally, the presence of key players in the region is further expected to propel the market over 2025.

Major players operating in the global leukemia therapeutics market include Novartis, AbbVie, Bristol-Myers Squibb, Roche, Amgen, Gilead sciences, Celgene, Eisai, AstraZeneca, Incyte Corporation, Johnson & Johnson, Biogen, Merck, PerkinElmer, Eli Lilly, Abbott, Sumitomo Dainippon Pharma, Thermo Fisher Scientific, Otsuka Holdings, Astellas Pharma and others. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in August 2017, Bristol-Myers Squibb acquired IFM Therapeutics in order to fortify its oncology product line.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study:

  • To analyze and forecast the market size of global leukemia therapeutics market.
  • To classify and forecast global leukemia therapeutics market based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and regional distribution.
  • To identify drivers and challenges for global leukemia therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global leukemia therapeutics market.
  • To identify and analyze the profile of leading players operating in global leukemia therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global leukemia therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Leukemia therapeutics manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to leukemia therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global leukemia therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Factor:

Artificial ionizing radiation

Viruses

Chemotherapy

Genetics

Immune suppression

Others

  • Market, By Severity:

Acute

Chronic

  • Market, By Blood Cell:

Lymphocytic

Myelogenous

  • Market, By Age Groups:

0-15

15-30

30-50

50+

  • Market, By Sex:

Male

Female

  • Market, By Treatment:

Targeted Therapy

Interferon Therapy

Radiation Therapy

Surgery

Stem Cell Transplantation

Drugs

Gene Therapy

Immunotherapy

Vaccine Therapy

Chemotherapy

Blood Transfusion

  • Market, By Diagnosis:

Blood test

Biopsy

Physical Exam

Imagining

  • CT-SCAN
  • X-RAY
  • MRI
  • Market, By Route of Administration:

Oral

Intravenous

Subcutaneous

Intramuscular

Intrathecal

  • Market, By Drugs:

Antimetabolites

Biosimilars

Asparagine-Specific Enzymes

Hormones (Corticosteroids)

Hypomethylating (Demethylating) Agents

Tyrosine Kinase Inhibitors

Others

  • Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global leukemia therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Leukemia Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Factor (Artificial ionizing radiation, Viruses, Chemotherapy, Genetics, Immune suppression, Others)
    • 5.2.2. By Severity (Acute, Chronic)
    • 5.2.3. By Blood Cell (Lymphocytic, Myelogenous)
    • 5.2.4. By Age Groups (0-15, 15-30, 30-50, 50+)
    • 5.2.5. By Sex (Male, Female)
    • 5.2.6. By Treatment (Targeted Therapy, Interferon Therapy, Radiation Therapy, Surgery, Stem Cell Transplantation, Drugs, Gene Therapy, Immunotherapy, Vaccine Therapy, Chemotherapy, Blood Transfusion)
    • 5.2.7. By Diagnosis (Blood test, Biopsy, Physical Exam, Imagining (CT-SCAN, X-RAY, MRI))
    • 5.2.8. By Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal)
    • 5.2.9. By Drugs (Antimetabolites, Biosimilars, Asparagine-Specific Enzymes, Hormones (Corticosteroids), Hypomethylating (Demethylating) Agents, Tyrosine Kinase Inhibitors, Others)
    • 5.2.10. By Company (2019)
    • 5.2.11. By Region
  • 5.3. Market Attractiveness Index

6. Asia-Pacific Leukemia Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Factor
    • 6.2.2. By Severity
    • 6.2.3. By Blood Cell
    • 6.2.4. By Age Groups
    • 6.2.5. By Sex
    • 6.2.6. By Treatment
    • 6.2.7. By Diagnosis
    • 6.2.8. By Route of Administration
    • 6.2.9. By Drugs
    • 6.2.10. By Country
  • 6.3. Market Attractiveness Index
  • 6.4. Asia-Pacific: Country Analysis
    • 6.4.1. China Leukemia Therapeutics Market Outlook
      • 6.4.1.1. Market Size & Forecast
        • 6.4.1.1.1. By Value
      • 6.4.1.2. Market Share & Forecast
        • 6.4.1.2.1. By Factor
        • 6.4.1.2.2. By Severity
        • 6.4.1.2.3. By Blood Cell
        • 6.4.1.2.4. By Age Groups
        • 6.4.1.2.5. By Sex
        • 6.4.1.2.6. By Treatment
        • 6.4.1.2.7. By Diagnosis
        • 6.4.1.2.8. By Route of Administration
        • 6.4.1.2.9. By Drugs
    • 6.4.2. India Leukemia Therapeutics Market Outlook
      • 6.4.2.1. Market Size & Forecast
        • 6.4.2.1.1. By Value
      • 6.4.2.2. Market Share & Forecast
        • 6.4.2.2.1. By Factor
        • 6.4.2.2.2. By Severity
        • 6.4.2.2.3. By Blood Cell
        • 6.4.2.2.4. By Age Groups
        • 6.4.2.2.5. By Sex
        • 6.4.2.2.6. By Treatment
        • 6.4.2.2.7. By Diagnosis
        • 6.4.2.2.8. By Route of Administration
        • 6.4.2.2.9. By Drugs
    • 6.4.3. Japan Leukemia Therapeutics Market Outlook
      • 6.4.3.1. Market Size & Forecast
        • 6.4.3.1.1. By Value
      • 6.4.3.2. Market Share & Forecast
        • 6.4.3.2.1. By Factor
        • 6.4.3.2.2. By Severity
        • 6.4.3.2.3. By Blood Cell
        • 6.4.3.2.4. By Age Groups
        • 6.4.3.2.5. By Sex
        • 6.4.3.2.6. By Treatment
        • 6.4.3.2.7. By Diagnosis
        • 6.4.3.2.8. By Route of Administration
        • 6.4.3.2.9. By Drugs
    • 6.4.4. South Korea Leukemia Therapeutics Market Outlook
      • 6.4.4.1. Market Size & Forecast
        • 6.4.4.1.1. By Value
      • 6.4.4.2. Market Share & Forecast
        • 6.4.4.2.1. By Factor
        • 6.4.4.2.2. By Severity
        • 6.4.4.2.3. By Blood Cell
        • 6.4.4.2.4. By Age Groups
        • 6.4.4.2.5. By Sex
        • 6.4.4.2.6. By Treatment
        • 6.4.4.2.7. By Diagnosis
        • 6.4.4.2.8. By Route of Administration
        • 6.4.4.2.9. By Drugs
    • 6.4.5. Singapore Leukemia Therapeutics Market Outlook
      • 6.4.5.1. Market Size & Forecast
        • 6.4.5.1.1. By Value
      • 6.4.5.2. Market Share & Forecast
        • 6.4.5.2.1. By Factor
        • 6.4.5.2.2. By Severity
        • 6.4.5.2.3. By Blood Cell
        • 6.4.5.2.4. By Age Groups
        • 6.4.5.2.5. By Sex
        • 6.4.5.2.6. By Treatment
        • 6.4.5.2.7. By Diagnosis
        • 6.4.5.2.8. By Route of Administration
        • 6.4.5.2.9. By Drugs
    • 6.4.6. Australia Leukemia Therapeutics Market Outlook
      • 6.4.6.1. Market Size & Forecast
        • 6.4.6.1.1. By Value
      • 6.4.6.2. Market Share & Forecast
        • 6.4.6.2.1. By Factor
        • 6.4.6.2.2. By Severity
        • 6.4.6.2.3. By Blood Cell
        • 6.4.6.2.4. By Age Groups
        • 6.4.6.2.5. By Sex
        • 6.4.6.2.6. By Treatment
        • 6.4.6.2.7. By Diagnosis
        • 6.4.6.2.8. By Route of Administration
        • 6.4.6.2.9. By Drugs

7. Europe Leukemia Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Factor
    • 7.2.2. By Severity
    • 7.2.3. By Blood Cell
    • 7.2.4. By Age Groups
    • 7.2.5. By Sex
    • 7.2.6. By Treatment
    • 7.2.7. By Diagnosis
    • 7.2.8. By Route of Administration
    • 7.2.9. By Drugs
    • 7.2.10. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. Europe: Country Analysis
    • 7.4.1. France Leukemia Therapeutics Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Factor
        • 7.4.1.2.2. By Severity
        • 7.4.1.2.3. By Blood Cell
        • 7.4.1.2.4. By Age Groups
        • 7.4.1.2.5. By Sex
        • 7.4.1.2.6. By Treatment
        • 7.4.1.2.7. By Diagnosis
        • 7.4.1.2.8. By Route of Administration
        • 7.4.1.2.9. By Drugs
    • 7.4.2. Germany Leukemia Therapeutics Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Factor
        • 7.4.2.2.2. By Severity
        • 7.4.2.2.3. By Blood Cell
        • 7.4.2.2.4. By Age Groups
        • 7.4.2.2.5. By Sex
        • 7.4.2.2.6. By Treatment
        • 7.4.2.2.7. By Diagnosis
        • 7.4.2.2.8. By Route of Administration
        • 7.4.2.2.9. By Drugs
    • 7.4.3. United Kingdom Leukemia Therapeutics Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Factor
        • 7.4.3.2.2. By Severity
        • 7.4.3.2.3. By Blood Cell
        • 7.4.3.2.4. By Age Groups
        • 7.4.3.2.5. By Sex
        • 7.4.3.2.6. By Treatment
        • 7.4.3.2.7. By Diagnosis
        • 7.4.3.2.8. By Route of Administration
        • 7.4.3.2.9. By Drugs
    • 7.4.4. Italy Leukemia Therapeutics Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Factor
        • 7.4.4.2.2. By Severity
        • 7.4.4.2.3. By Blood Cell
        • 7.4.4.2.4. By Age Groups
        • 7.4.4.2.5. By Sex
        • 7.4.4.2.6. By Treatment
        • 7.4.4.2.7. By Diagnosis
        • 7.4.4.2.8. By Route of Administration
        • 7.4.4.2.9. By Drugs

8. North America Leukemia Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Factor
    • 8.2.2. By Severity
    • 8.2.3. By Blood Cell
    • 8.2.4. By Age Groups
    • 8.2.5. By Sex
    • 8.2.6. By Treatment
    • 8.2.7. By Diagnosis
    • 8.2.8. By Route of Administration
    • 8.2.9. By Drugs
    • 8.2.10. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Leukemia Therapeutics Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Factor
        • 8.4.1.2.2. By Severity
        • 8.4.1.2.3. By Blood Cell
        • 8.4.1.2.4. By Age Groups
        • 8.4.1.2.5. By Sex
        • 8.4.1.2.6. By Treatment
        • 8.4.1.2.7. By Diagnosis
        • 8.4.1.2.8. By Route of Administration
        • 8.4.1.2.9. By Drugs
    • 8.4.2. Mexico Leukemia Therapeutics Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Factor
        • 8.4.2.2.2. By Severity
        • 8.4.2.2.3. By Blood Cell
        • 8.4.2.2.4. By Age Groups
        • 8.4.2.2.5. By Sex
        • 8.4.2.2.6. By Treatment
        • 8.4.2.2.7. By Diagnosis
        • 8.4.2.2.8. By Route of Administration
        • 8.4.2.2.9. By Drugs
    • 8.4.3. Canada Leukemia Therapeutics Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Factor
        • 8.4.3.2.2. By Severity
        • 8.4.3.2.3. By Blood Cell
        • 8.4.3.2.4. By Age Groups
        • 8.4.3.2.5. By Sex
        • 8.4.3.2.6. By Treatment
        • 8.4.3.2.7. By Diagnosis
        • 8.4.3.2.8. By Route of Administration
        • 8.4.3.2.9. By Drugs

9. South America Leukemia Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Factor
    • 9.2.2. By Severity
    • 9.2.3. By Blood Cell
    • 9.2.4. By Age Groups
    • 9.2.5. By Sex
    • 9.2.6. By Treatment
    • 9.2.7. By Diagnosis
    • 9.2.8. By Route of Administration
    • 9.2.9. By Drugs
    • 9.2.10. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. South America: Country Analysis
    • 9.4.1. Brazil Leukemia Therapeutics Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Factor
        • 9.4.1.2.2. By Severity
        • 9.4.1.2.3. By Blood Cell
        • 9.4.1.2.4. By Age Groups
        • 9.4.1.2.5. By Sex
        • 9.4.1.2.6. By Treatment
        • 9.4.1.2.7. By Diagnosis
        • 9.4.1.2.8. By Route of Administration
        • 9.4.1.2.9. By Drugs
    • 9.4.2. Argentina Leukemia Therapeutics Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Factor
        • 9.4.2.2.2. By Severity
        • 9.4.2.2.3. By Blood Cell
        • 9.4.2.2.4. By Age Groups
        • 9.4.2.2.5. By Sex
        • 9.4.2.2.6. By Treatment
        • 9.4.2.2.7. By Diagnosis
        • 9.4.2.2.8. By Route of Administration
        • 9.4.2.2.9. By Drugs
    • 9.4.3. Colombia Leukemia Therapeutics Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Factor
        • 9.4.3.2.2. By Severity
        • 9.4.3.2.3. By Blood Cell
        • 9.4.3.2.4. By Age Groups
        • 9.4.3.2.5. By Sex
        • 9.4.3.2.6. By Treatment
        • 9.4.3.2.7. By Diagnosis
        • 9.4.3.2.8. By Route of Administration
        • 9.4.3.2.9. By Drugs

10. Middle East and Africa Leukemia Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Factor
    • 10.2.2. By Severity
    • 10.2.3. By Blood Cell
    • 10.2.4. By Age Groups
    • 10.2.5. By Sex
    • 10.2.6. By Treatment
    • 10.2.7. By Diagnosis
    • 10.2.8. By Route of Administration
    • 10.2.9. By Drugs
    • 10.2.10. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. MEA: Country Analysis
    • 10.4.1. South Africa Leukemia Therapeutics Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Factor
        • 10.4.1.2.2. By Severity
        • 10.4.1.2.3. By Blood Cell
        • 10.4.1.2.4. By Age Groups
        • 10.4.1.2.5. By Sex
        • 10.4.1.2.6. By Treatment
        • 10.4.1.2.7. By Diagnosis
        • 10.4.1.2.8. By Route of Administration
        • 10.4.1.2.9. By Drugs
    • 10.4.2. Saudi Arabia Leukemia Therapeutics Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Factor
        • 10.4.2.2.2. By Severity
        • 10.4.2.2.3. By Blood Cell
        • 10.4.2.2.4. By Age Groups
        • 10.4.2.2.5. By Sex
        • 10.4.2.2.6. By Treatment
        • 10.4.2.2.7. By Diagnosis
        • 10.4.2.2.8. By Route of Administration
        • 10.4.2.2.9. By Drugs
    • 10.4.3. UAE Leukemia Therapeutics Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Factor
        • 10.4.3.2.2. By Severity
        • 10.4.3.2.3. By Blood Cell
        • 10.4.3.2.4. By Age Groups
        • 10.4.3.2.5. By Sex
        • 10.4.3.2.6. By Treatment
        • 10.4.3.2.7. By Diagnosis
        • 10.4.3.2.8. By Route of Administration
        • 10.4.3.2.9. By Drugs

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Competition Outlook
  • 13.2. Players Profiled (Leading Companies)
    • 13.2.1. Novartis
    • 13.2.2. AbbVie
    • 13.2.3. Bristol-Myers Squibb
    • 13.2.4. Roche
    • 13.2.5. Amgen
    • 13.2.6. Gilead sciences
    • 13.2.7. Celgene
    • 13.2.8. Eisai
    • 13.2.9. AstraZeneca
    • 13.2.10. Incyte Corporation
    • 13.2.11. Johnson & Johnson
    • 13.2.12. Biogen
    • 13.2.13. Merck
    • 13.2.14. PerkinElmer
    • 13.2.15. Eli Lilly
    • 13.2.16. Abbott
    • 13.2.17. Sumitomo Dainippon Pharma
    • 13.2.18. Thermo Fisher Scientific
    • 13.2.19. Otsuka Holdings
    • 13.2.20. Astellas Pharma

14. Strategic Recommendations

15. About Us & Disclaimer

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.